In tumor cells, RTKs and MYC cooperate to promote a malignant phenotype [132]: aberrant activation of RTKs, through overexpression or activating mutations, increases the transcriptional expression of MYC by continuously stimulating the RAS/RAF/MEK and PI3K/AKT pathways [133]. Here, AKT1 is linked to neoplasm.